DK2868660T3 - Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse - Google Patents
Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelseInfo
- Publication number
- DK2868660T3 DK2868660T3 DK13813275.8T DK13813275T DK2868660T3 DK 2868660 T3 DK2868660 T3 DK 2868660T3 DK 13813275 T DK13813275 T DK 13813275T DK 2868660 T3 DK2868660 T3 DK 2868660T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- atom
- substituent
- alkoxy
- effect potentiator
- Prior art date
Links
- -1 IMIDAZOOXAZINE COMPOUND Chemical class 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012148850 | 2012-07-02 | ||
| JP2012215902 | 2012-09-28 | ||
| PCT/JP2013/068054 WO2014007217A1 (ja) | 2012-07-02 | 2013-07-01 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2868660T3 true DK2868660T3 (da) | 2018-01-29 |
Family
ID=49881973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13813275.8T DK2868660T3 (da) | 2012-07-02 | 2013-07-01 | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9375434B2 (da) |
| EP (1) | EP2868660B1 (da) |
| JP (1) | JP5855250B2 (da) |
| KR (2) | KR101671761B1 (da) |
| AU (1) | AU2013284570B2 (da) |
| DK (1) | DK2868660T3 (da) |
| ES (1) | ES2660215T3 (da) |
| HU (1) | HUE036188T2 (da) |
| NO (1) | NO2868660T3 (da) |
| PL (1) | PL2868660T3 (da) |
| PT (1) | PT2868660T (da) |
| RU (1) | RU2618423C2 (da) |
| TW (1) | TWI534149B (da) |
| WO (1) | WO2014007217A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE053322T2 (hu) * | 2013-06-20 | 2021-06-28 | Taiho Pharmaceutical Co Ltd | Eljárás PI3K/AKT/mTOR inhibitor terápiás hatékonyságának elõrejelzésére PHLDA1 vagy PIK3C2B expressziója alapján |
| KR101974254B1 (ko) | 2013-07-18 | 2019-04-30 | 다이호야쿠힌고교 가부시키가이샤 | Fgfr 저해제의 간헐 투여용 항종양제 |
| WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
| WO2016136928A1 (ja) * | 2015-02-27 | 2016-09-01 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP4470621A3 (en) | 2018-03-19 | 2025-05-07 | Taiho Pharmaceutical Co., Ltd. | Use of sodium alkyl sulfate |
| US20220354858A1 (en) * | 2019-06-21 | 2022-11-10 | Taiho Pharmaceutical Co., Ltd. | Method for treating malignant tumor |
| CN115443267B (zh) | 2020-04-28 | 2025-09-05 | 巴斯夫欧洲公司 | 杀害虫化合物 |
| JP2024505252A (ja) * | 2021-02-01 | 2024-02-05 | 大鵬薬品工業株式会社 | Pten不活性化突然変異を有する患者における癌の治療 |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
| CN119912475B (zh) * | 2025-03-06 | 2026-01-06 | 复旦大学 | 用作tlr2拮抗剂的化合物或其衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022205B2 (en) | 2006-08-08 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as PI3K inhibitor and use thereof |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| DE602008005894D1 (de) * | 2007-08-14 | 2011-05-12 | Bayer Schering Pharma Ag | Kondensierte imidazole zur krebsbehandlung |
| US9451809B2 (en) | 2008-05-29 | 2016-09-27 | Nike, Inc. | Article of footwear with a marking system |
| AU2009255358A1 (en) | 2008-06-03 | 2009-12-10 | Msd K.K. | Inhibitors of Akt activity |
| WO2010088177A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2403339B1 (en) * | 2009-03-06 | 2017-01-18 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an akt inhibitor and other anticancer agents |
| WO2010104933A1 (en) | 2009-03-11 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| ES2567605T3 (es) * | 2011-04-06 | 2016-04-25 | Taiho Pharmaceutical Co., Ltd. | Nuevo compuesto de imidazo-oxazina o sal del mismo |
-
2013
- 2013-07-01 NO NO13813275A patent/NO2868660T3/no unknown
- 2013-07-01 HU HUE13813275A patent/HUE036188T2/hu unknown
- 2013-07-01 WO PCT/JP2013/068054 patent/WO2014007217A1/ja not_active Ceased
- 2013-07-01 RU RU2015103151A patent/RU2618423C2/ru active
- 2013-07-01 AU AU2013284570A patent/AU2013284570B2/en active Active
- 2013-07-01 KR KR1020157001880A patent/KR101671761B1/ko active Active
- 2013-07-01 US US14/407,745 patent/US9375434B2/en active Active
- 2013-07-01 DK DK13813275.8T patent/DK2868660T3/da active
- 2013-07-01 JP JP2014523736A patent/JP5855250B2/ja active Active
- 2013-07-01 PL PL13813275T patent/PL2868660T3/pl unknown
- 2013-07-01 ES ES13813275.8T patent/ES2660215T3/es active Active
- 2013-07-01 EP EP13813275.8A patent/EP2868660B1/en active Active
- 2013-07-01 TW TW102123523A patent/TWI534149B/zh active
- 2013-07-01 KR KR1020167030063A patent/KR20160128456A/ko not_active Withdrawn
- 2013-07-01 PT PT138132758T patent/PT2868660T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI534149B (zh) | 2016-05-21 |
| WO2014007217A1 (ja) | 2014-01-09 |
| JPWO2014007217A1 (ja) | 2016-06-02 |
| ES2660215T3 (es) | 2018-03-21 |
| KR20150023870A (ko) | 2015-03-05 |
| HUE036188T2 (hu) | 2018-06-28 |
| PL2868660T3 (pl) | 2018-05-30 |
| US20150164909A1 (en) | 2015-06-18 |
| US9375434B2 (en) | 2016-06-28 |
| AU2013284570B2 (en) | 2016-04-14 |
| NO2868660T3 (da) | 2018-05-26 |
| TW201408671A (zh) | 2014-03-01 |
| EP2868660A1 (en) | 2015-05-06 |
| AU2013284570A1 (en) | 2015-01-22 |
| JP5855250B2 (ja) | 2016-02-09 |
| PT2868660T (pt) | 2018-02-02 |
| RU2618423C2 (ru) | 2017-05-03 |
| KR20160128456A (ko) | 2016-11-07 |
| EP2868660B1 (en) | 2017-12-27 |
| RU2015103151A (ru) | 2016-08-20 |
| EP2868660A4 (en) | 2016-03-23 |
| KR101671761B1 (ko) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013100566A8 (en) | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | |
| PH12013501873A1 (en) | Novel imidazo-oxazine compound or salt thereof | |
| EA201390885A1 (ru) | Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| EA201390884A1 (ru) | Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса | |
| IN2015MN00405A (da) | ||
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX2014011829A (es) | Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales. | |
| PH12013501809A1 (en) | Endoparasite control agent | |
| MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
| PH12017501255B1 (en) | Tricyclic spiro compound | |
| MX2014000359A (es) | Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii. | |
| MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
| EA201491525A1 (ru) | Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae | |
| HK1203932A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
| MX364207B (es) | Inhibidores de agrecanasa. | |
| PH12016500152A1 (en) | Novel triazine derivative | |
| IN2014MN02485A (da) | ||
| MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
| PH12014500212A1 (en) | Pyrrolidine-3-ylacetic acid derivative | |
| AR092772A1 (es) | Derivado de 7-azaindol | |
| MX2012002529A (es) | Agente terapeutico para trastornos de ansiedad. | |
| PH12015501056A1 (en) | 2-pyridone compound | |
| WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 |